Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine in CEACAM5-positive metastatic breast cancer and pancreatic adenocarcinoma
NCT04659603Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of tusamitamab ravtansine in breast cancer and pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Sanofi. Primary endpoints: Objective Response Rate at 43.3 weeks and Dose Limiting Toxicities at 4 weeks. Started Mar 2021; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
breast cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04659603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659603.